Latest From Yuhan Corp.
Through its Provention collaboration, Amgen partnered with the team that worked on AMG 714 at Celimmune, which the big biotech bought in 2017. Lilly will partner with NextCure to use the latter's FIND-IO platform for immuno-oncology drug discovery.
Yuhan inks long-awaited, major global license agreement for its novel third-generation EGFR TKI with Janssen, in a $1.2bn deal poised to boost the South Korean firm's ongoing R&D efforts in key therapeutic areas, while Janssen will further beef up its oncology portfolio. But competition with entrenched rival Tagrisso awaits.
Taking into consideration global and domestic trends, South Korean pharmas are increasingly finding their own strategies to seek open innovation and collaborations to develop novel new drugs. Two leading firms from the country shared their know-how and showcased successful open innovation cases during a recent gathering organized by a national industry association.
South Korean pharma firm licenses out to US venture Spine Biopharma novel peptide drug for degenerative disc disease YH14618, despite a Phase II failure and trial halt in 2016.
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Infectious & Viral Diseases
- Metabolic Disorders
- South Korea
- Pacific Rim
- Parent & Subsidiaries
- Yuhan Corp.
- Senior Management
- Jung Hee Lee, Pres. & CEO
- Contact Info
Phone: 2 828 0181
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.